Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA progress, and launch potential by 2026.

Anito-cel’s Phase 3 trial results are expected by yearend 2024, with a possible BLA submission in 2025, entering a $34.4 billion market. Despite a premium valuation, ...

Study participants received lymphodepletion chemotherapy followed by a single infusion of anito-cel at one of two dose levels (100 × 10 6 or 300 × 10 6 CAR T cells).

Anito: Defend a Land Enraged Wrap Report Gabby Dizon and Niel Dagondon on Anino Entertainment's title, a finalist in the 2004 Independent Games Festival Anino's finalist entry in the 2004 ...

Philippine indie game developer Anino Entertainment has today announced the launch of Anito: Defend a Land Enraged. The adventure role-playing game, which was recently confirmed as a finalist in ...